Washington
Alzheimer's disease clinical trials in Washington
15 Alzheimer's disease studies are recruiting participants at sites in 4 cities across Washington as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Washington city with a recruiting study
Seattle (8), Bellevue (5), Kirkland (2), Tacoma (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Recently updated studies in Washington
Basic details from each study's public record (the 12 most recently updated of 15). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- MapLight Therapeutics
- Recruiting in
- Bellevue
- Registry record
- NCT06887192 · updated
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Phase 2
- Ages 55 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Kirkland
- Registry record
- NCT07589595 · updated
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Phase 2
- Ages 55 and older
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Recruiting in
- Bellevue
- Registry record
- NCT06540833 · updated
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Kirkland
- Registry record
- NCT07011745 · updated
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Phase 3
- Ages 55 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Bellevue · Tacoma
- Registry record
- NCT07602582 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Recruiting in
- Bellevue
- Registry record
- NCT06585787 · updated
Alzheimer's Tau Platform: Master Protocol
- Phase 2
- Ages 50 to 80
- All sexes
- Sponsor
- Paul S. Aisen
- Recruiting in
- Seattle
- Registry record
- NCT06957418 · updated
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- Phase 2
- Ages 55 to 80
- All sexes
- Sponsor
- Lighthouse Pharmaceuticals, Inc.
- Recruiting in
- Bellevue
- Registry record
- NCT06847321 · updated
Dominantly Inherited Alzheimer Network (DIAN)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Recruiting in
- Seattle
- Registry record
- NCT00869817 · updated
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Fred Hutchinson Cancer Center
- Recruiting in
- Seattle
- Registry record
- NCT06922188 · updated
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eidos Therapeutics, a BridgeBio company
- Recruiting in
- Seattle
- Registry record
- NCT06563895 · updated
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Recruiting in
- Seattle
- Registry record
- NCT05552157 · updated
Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Washington on ClinicalTrials.gov.
Ask about studies in Washington
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections